Overview

To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

Status:
Recruiting

Trial end date:
2024-08-31

Target enrollment:

Participant gender:

Summary

To investigate the efficacy and safety of a single injection of GenSci094 to induce multi-follicular development for controlled ovarian stimulation using daily recombinant FSH (recFSH) as a reference. The primary hypothesis is that a single injection of GenSci094 is non-inferior to daily treatment with recFSH in initiating multi-follicular growth.

Phase:

Phase 3

Details

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborator:

Sixth Affiliated Hospital, Sun Yat-sen University

Treatments:

Follicle Stimulating Hormone
Ganirelix
Progesterone